Who is sponsoring NCT06256484?

NCT06256484 is sponsored by Atara Biotherapeutics.

What drugs are being tested in NCT06256484?

Interventions in NCT06256484: ATA3219.

What condition does NCT06256484 study?

NCT06256484 studies Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Is NCT06256484 still recruiting?

NCT06256484 is currently terminated. Last updated 11 March 2026.

Last reviewed 2026-03-11 · How we verify

NCT06256484

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Terminated Phase 1 Last updated 11 March 2026

What this trial tests

Phase 1 trial testing ATA3219 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma in 1 participant. Terminated before completion.

Timeline

6 September 2024

Primary endpoint
3 March 2025

30 March 2025

Quick facts

Lead sponsor	Atara Biotherapeutics
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	6 September 2024
Primary completion	3 March 2025
Estimated completion	30 March 2025
Sites	6 locations across United States, Australia

Drugs / interventions tested

ATA3219 — full drug profile →

Conditions studied

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma — all drugs for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma →

Sponsor

Atara Biotherapeutics — full company profile →

Who can join

Adults 18 to 120, any sex, with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

"Off-The-Shelf" allogeneic chimeric antigen receptor T-cell therapy for B-cell malignancies: current clinical evidence and challenges.
Mohty R, Lazaryan A. · · 2024 · cited 19× · PMID 39055556 · DOI 10.3389/fonc.2024.1433432
EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes.
Law N, Logan C, Taplitz R. · · 2024 · cited 10× · PMID 39205268 · DOI 10.3390/v16081294
Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis.
Biederstädt A, Bassermann F, Hecker JS. · · 2025 · cited 6× · PMID 40698082 · DOI 10.3389/fimmu.2025.1585556
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells.
Boccellato E, Comba L, Tavarozzi R, Castellino C, et al · · 2025 · cited 2× · PMID 40647536 · DOI 10.3390/cancers17132239

Verify or expand the search:

Other trials of ATA3219

Trials testing the same drug.

NCT06429800 — A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus · Phase 1 · withdrawn

Other recruiting trials for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07376642 — A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, · EARLY_PHASE1 · recruiting
NCT07073833 — The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma · Phase 1 · recruiting
NCT06561425 — A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma · Phase 1, PHASE2 · active not recruiting

Other Atara Biotherapeutics trials

Trials by the same sponsor.

NCT06429800 — A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus · Phase 1 · withdrawn
NCT03769467 — Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma · Phase 1, PHASE2 · terminated
NCT03283826 — Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis · Phase 1, PHASE2 · terminated
NCT02822495 — Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies · no longer available
NCT03010332 — Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06256484 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Atara Biotherapeutics
Last refreshed: 11 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06256484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing